Protagonist Therapeutics is a clinical stage biopharmaceutical company that utilizes a proprietary technology platform to discover and develop novel peptide-based drugs to transform existing treatment paradigms for patients with significant unmet medical needs. PTG-300 is an injectable hepcidin mimetic for the potential treatment of anemia and iron overload related rare blood diseases, and is currently in a Phase 2 study in beta-thalassemia. PTG-200 is an oral, gut-restricted interleukin-23 receptor specific antagonist peptide in development for the treatment of inflammatory bowel disease. The Company has a worldwide license and collaboration agreement with Janssen Biotech for the clinical development of PTG-200 and a Phase 2 study in Crohnâs disease is expected to commence in 2019. PN-943, currently in a Phase 1 study, is an oral, gut-restricted alpha-4-beta-7 integrin specific antagonist peptide in development for the treatment of inflammatory bowel disease. Protagonist is headquartered in Newark, California, with pre-clinical and clinical development staff in California and discovery operations in both California and Brisbane, Queensland, Australia. For further information, please visit http://www.protagonist-inc.com. Source
No articles found.
argenx is a clinical-stage biotechnology company developing a deep pipeline of dif...
argenx is a clinical-stage biotechnology compan...
Blueprint Medicines is a precision therapy company striving to improve human healt...
Blueprint Medicines is a precision therapy comp...
Flexion Therapeutics is a biopharmaceutical company focused on the development and...
Flexion Therapeutics is a biopharmaceutical com...
Atara Biotherapeutics is a leading off-the-shelf, allogeneic T-cell immunotherapy ...
Atara Biotherapeutics is a leading off-the-shel...
We are an international biotechnology company that is focused in the field of rege...
We are an international biotechnology company t...
MorphoSys (FSE & NASDAQ: MOR) is a clinical-stage biopharmaceutical company dedica...
MorphoSys (FSE & NASDAQ: MOR) is a clinical-sta...
Novan, Inc. is a clinical development-stage biotechnology company focused on lever...
Novan, Inc. is a clinical development-stage bio...
Join the National Investor Network and get the latest information with your interests in mind.